Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries

Reuters11-07

Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries

Overview

SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year
Company attributes revenue decline to lower product sales, especially TPOXX deliveries
SIGA focuses on securing new procurement contracts for future revenue growth

Outlook

SIGA focuses on securing new procurement contracts for future revenue growth

Result Drivers

LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries
U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries
INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$6.40 mln

Analyst Coverage

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release: ID:nGNX7g5NW3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581486500?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581486500","market":"fut","top_or_hot":-1,"title":"Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries</title></head><body><p><span>Overview</span></p><ul><li><p>SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year</p></li><li><p>Company attributes revenue decline to lower product sales, especially TPOXX deliveries</p></li><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries</p></li><li><p>U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries</p></li><li><p>INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$6.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX7g5NW3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries</title></head><body><p><span>Overview</span></p><ul><li><p>SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year</p></li><li><p>Company attributes revenue decline to lower product sales, especially TPOXX deliveries</p></li><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries</p></li><li><p>U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries</p></li><li><p>INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$6.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX7g5NW3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SIGA","symbol_name":"SIGA Technologies Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1I2:1","article_id":"2581486500","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581486500","pubTimestamp":1762463630,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveriesOverviewSIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last yearCompan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SIGA":"SIGA Technologies Inc","BK4007":"制药","BK4583":"猴痘概念"},"translate_title":"抗病毒疗法开发商SIGA第三季度收入因TPOXX交付量下降而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SIGA":0.9},"content_text":"Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveriesOverviewSIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last yearCompany attributes revenue decline to lower product sales, especially TPOXX deliveriesSIGA focuses on securing new procurement contracts for future revenue growthOutlookSIGA focuses on securing new procurement contracts for future revenue growthResult DriversLOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveriesU.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveriesINTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six yearsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$6.40 mlnAnalyst CoverageThe stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months agoPress Release: ID:nGNX7g5NW3For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581486500","isCrawlerRequest":true}